8月20日，中共中央政治局常委、国务院总理李强在北京调研生物医药产业发展情况。这是李强在百济神州（北京）生物科技 有限公司调研有关新药研发等情况。新华社记者 刘彬 摄 李强首先来到昌平实验室，听取有关重大疾病诊疗技术和设备设施研发进展汇报。李强指出，要在生物医药这条新赛道上跑 出加速度，必须加大科技创新力度。希望大家锚定国际前沿和重要领域，重点围绕新靶点、新化合物、新作用机理等，集中协同 开展科研攻关，多产出重大原创性成果，多培养生命科学领域高端人才，不断夯实我国生物医药产业发展根基。 在百济神州（北京）生物科技有限公司，李强了解有关新药研发情况，察看药物化学实验室，细致询问生产流程。李强说， 我国健康产业市场空间巨大，创新药发展前景广阔。要及时发现临床价值高、转化潜力大的创新药项目，加强跟踪服务，推动医 疗机构配备使用。要大力培育优质企业，在人才、融资等方面给予政策支持，鼓励企业深化国际合作，持续提升企业创新力、竞 争力。 李强在北京调研生物医药产业发展时强调 加大高质量科技供给和政策支持 着力推动生物医药产业提质升级 新华社北京8月20日电（记者 邹伟）中共中央政治局常委、国务院总理李强8月20日在北京调 ...

Core Insights - The Chinese government emphasizes the importance of the biopharmaceutical industry for enhancing public health and aims to accelerate innovation and development in this sector [2][4]. Group 1: Government Initiatives - The government plans to increase high-quality technological supply and policy support to promote the biopharmaceutical industry's upgrade and innovation [2][4]. - There is a focus on strengthening original innovation and tackling key core technologies, leveraging both government and market resources to achieve breakthroughs [4]. Group 2: Industry Development - The biopharmaceutical market in China is seen as having significant growth potential, with a strong emphasis on developing innovative drugs with high clinical value and transformation potential [3]. - Companies are encouraged to deepen international cooperation and enhance their innovation and competitiveness through policy support in talent and financing [3]. Group 3: Research and Collaboration - The government advocates for collaborative research efforts targeting new drug targets, compounds, and mechanisms, aiming to produce significant original results and cultivate high-end talent in life sciences [2][3]. - There is a push for the establishment of shared research platforms and one-stop R&D solutions to facilitate the integration of medical and engineering fields, as well as industry-academia collaboration [3]. Group 4: Technology Integration - The integration of artificial intelligence in various stages of drug development, clinical trials, and production is highlighted as a means to enhance the industry's development [4]. - The government aims to optimize policies related to drug procurement and negotiation mechanisms to support the application of high-level innovative drugs [4].

Group 1 - The Chinese government emphasizes the importance of the biopharmaceutical industry for public health and aims to enhance innovation and policy support to improve the quality and efficiency of drug development [1][2] - A recent meeting highlighted the need for original innovation and key technology breakthroughs, with a focus on integrating artificial intelligence into various stages of drug development and production [2] - The National Healthcare Security Administration has approved 534 drugs for the national basic medical insurance directory, indicating a growing support for innovative drugs [2][3] Group 2 - The biopharmaceutical sector in China is experiencing rapid growth, with over 100 licensing transactions worth $52.3 billion in 2024, marking a significant increase from $41.9 billion in 2023 [3] - The number of outbound licensing transactions has tripled compared to inbound transactions, showcasing China's increasing competitiveness in the global pharmaceutical market [3] - The market sentiment for innovative drugs has been positively impacted by recent supportive policies, with a focus on optimizing drug procurement and negotiation mechanisms [4][6] Group 3 - The oncology sector is highlighted as a key area for innovation, particularly in antibody-drug conjugates (ADCs) and immunotherapy, with significant opportunities for new product development [5] - The overall sentiment in the innovative drug sector remains optimistic, with expectations for continued policy support and improved commercial viability [6] - Companies like 基石药业-B, 和誉-B, 和铂医药, and 信达生物 are actively involved in innovative drug development and strategic partnerships, indicating a robust pipeline of new therapies [7][8]

Core Viewpoint - The article emphasizes the need for high-quality technological supply and policy support to enhance the development of the biopharmaceutical industry in China, focusing on innovation and the production of effective new drugs to improve public health [1][2][3]. Group 1: Government Initiatives - The Chinese government aims to accelerate the biopharmaceutical sector by increasing technological innovation and focusing on new targets, compounds, and mechanisms [1]. - There is a significant market potential for innovative drugs in China's health industry, and the government encourages the identification of high clinical value projects and their integration into medical institutions [2]. - The government plans to enhance original innovation and tackle key technologies by mobilizing resources from both the government and the market [3]. Group 2: Industry Development - The article highlights the importance of creating a supportive environment for biopharmaceutical companies, including talent cultivation and financial support [2]. - It stresses the need for a comprehensive service model that integrates research and development, production, and application to facilitate the commercialization of scientific achievements [2]. - The integration of artificial intelligence in various stages of drug development and production is emphasized to improve efficiency and effectiveness [3]. Group 3: Traditional Medicine - The article calls for the revitalization of traditional Chinese medicine through modern scientific methods, enhancing its theoretical and practical frameworks [3].

Core Viewpoint - The Chinese government emphasizes the importance of accelerating the development of the biopharmaceutical industry through enhanced technological innovation and policy support, aiming to improve public health and foster high-quality drug development [1][2]. Group 1: Industry Development - The biopharmaceutical industry is identified as a strategic emerging industry that significantly impacts public health and well-being [2]. - There is a call for increased investment in original innovation and key core technology breakthroughs, leveraging both government and market resources to foster innovation [2]. - The market potential for the health industry is highlighted, with a focus on the promising future of innovative drug development [1]. Group 2: Innovation and Collaboration - The government encourages the establishment of shared research and development platforms to accelerate the transformation of biopharmaceutical innovations into practical applications [2]. - There is an emphasis on the integration of artificial intelligence to enhance various stages of drug development, clinical trials, and production processes [2]. - The importance of fostering high-quality enterprises through policy support in talent and financing is stressed, alongside promoting international collaboration [1]. Group 3: Policy and Regulatory Framework - The need for improved coordination in product research, evaluation, and management policies is highlighted to optimize drug procurement and negotiation mechanisms [2]. - The government aims to enhance guidance on the application of high-level innovative drugs, ensuring a supportive regulatory environment for the biopharmaceutical sector [2]. - There is a focus on modernizing and industrializing traditional Chinese medicine by applying modern scientific theories and technologies [2].